The cost of Humalog 50/50, an insulin lispro protamine suspension and insulin lispro injection combination, can vary depending on several factors. These include the dosage, the quantity purchased, insurance coverage, and the pharmacy where it is obtained. Without specific insurance details or purchase location, providing an exact price is not possible.
What is Humalog 50/50?
Humalog 50/50 is a type of insulin used to manage blood sugar levels in adults and children with diabetes. It is a combination of 50% insulin lispro protamine suspension and 50% insulin lispro injection [1]. This formulation is designed to provide both rapid-acting and intermediate-acting insulin coverage.
How much does Humalog 50/50 typically cost?
The retail price for a vial of Humalog 50/50 can range from approximately $150 to $300 or more, while a box of pens (e.g., KwikPens) can cost several hundred dollars [2]. These figures represent out-of-pocket costs before any insurance benefits or discounts are applied.
What affects the price of Humalog 50/50?
Several factors influence the final cost of Humalog 50/50:
* Insurance Coverage: Prescription drug plans often have formularies that list covered medications and their associated costs (copays or coinsurance). The tier of the drug on the formulary significantly impacts the patient's out-of-pocket expense.
* Pharmacy Pricing: Different pharmacies may have varying pricing structures for prescription medications.
* Manufacturer Coupons and Discount Programs: Eli Lilly and Company, the manufacturer of Humalog, offers savings cards and discount programs that can reduce the cost for eligible patients [3].
* Quantity and Formulation: The price can differ between vials and pre-filled pens, as well as based on the number of units or pens purchased.
* Market Conditions and Competition: The availability of alternative insulin products and the overall insulin market can influence pricing.
Are there discount programs or patient assistance for Humalog 50/50?
Yes, Eli Lilly and Company provides programs to help lower the cost of Humalog for eligible individuals. The Humalog Savings Card, for instance, can reduce the out-of-pocket cost for eligible commercially insured patients. For uninsured or underinsured patients, Lilly Cares Foundation offers free medication through a patient assistance program, subject to income and eligibility requirements [3].
How does Humalog 50/50 compare to other insulin formulations?
Humalog 50/50 offers a combination of rapid and intermediate-acting insulin. Rapid-acting insulins, like insulin lispro (the fast-acting component in Humalog 50/50), begin working within 15 minutes, peak in 1 to 2 hours, and last 3 to 5 hours. Intermediate-acting insulins, like insulin lispro protamine suspension (the longer-acting component in Humalog 50/50), typically start working within 2 to 4 hours, peak in 4 to 12 hours, and last 12 to 18 hours. This dual action aims to cover meals and provide basal insulin coverage for a portion of the day. Other insulin formulations include rapid-acting, short-acting, intermediate-acting, and long-acting insulins, as well as different pre-mixed combinations [1].
When does the patent for Humalog expire?
The original patents for Humalog have expired, which has allowed for the development of biosimilar versions. For instance, Semglee, a biosimilar insulin glargine, is available, though insulin lispro biosimilars are also in development and on the market. Information on specific patent expiry dates for different formulations and regions can be tracked through resources like DrugPatentWatch.com [4].
Can biosimilars for Humalog 50/50 be manufactured?
Yes, biosimilars can be developed and manufactured for biologics like insulin. Eli Lilly's Humalog has faced competition from biosimilar insulin lispro products. These biosimilars are highly similar to the reference product and have no clinically meaningful differences in terms of safety, purity, and potency [1]. The availability of biosimilars can potentially lead to lower costs for patients.